INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,166,166 | -39.7% | 463,931 | -26.7% | 0.01% | -40.0% |
| Q2 2023 | $40,076,114 | +142667.0% | 632,914 | +22.1% | 0.02% | +25.0% |
| Q1 2023 | $28,071 | -62.0% | 518,388 | -62.9% | 0.02% | -61.0% |
| Q4 2022 | $73,909 | -99.9% | 1,396,620 | -25.0% | 0.04% | -21.2% |
| Q3 2022 | $86,613,000 | +39.6% | 1,861,449 | +71.2% | 0.05% | +33.3% |
| Q2 2022 | $62,062,000 | +35.1% | 1,087,277 | +44.9% | 0.04% | +56.0% |
| Q1 2022 | $45,921,000 | +30.8% | 750,469 | +11.9% | 0.02% | +38.9% |
| Q4 2021 | $35,102,000 | +22.4% | 670,657 | -12.8% | 0.02% | +5.9% |
| Q3 2021 | $28,681,000 | +9.3% | 769,351 | +19.7% | 0.02% | +6.2% |
| Q2 2021 | $26,246,000 | -3.1% | 642,978 | -19.4% | 0.02% | -15.8% |
| Q1 2021 | $27,078,000 | -46.6% | 798,052 | -49.9% | 0.02% | -48.6% |
| Q4 2020 | $50,694,000 | -3.4% | 1,594,153 | -22.1% | 0.04% | -43.1% |
| Q3 2020 | $52,498,000 | +861.7% | 2,045,896 | +862.1% | 0.06% | +712.5% |
| Q2 2020 | $5,459,000 | -22.1% | 212,655 | -53.4% | 0.01% | -50.0% |
| Q1 2020 | $7,011,000 | -66.5% | 456,133 | -25.2% | 0.02% | -38.5% |
| Q4 2019 | $20,925,000 | +122.9% | 609,854 | -51.5% | 0.03% | +73.3% |
| Q3 2019 | $9,389,000 | +434.4% | 1,256,968 | +828.7% | 0.02% | +400.0% |
| Q2 2019 | $1,757,000 | -83.0% | 135,352 | -84.1% | 0.00% | -81.2% |
| Q1 2019 | $10,355,000 | -3.1% | 850,158 | -9.4% | 0.02% | 0.0% |
| Q4 2018 | $10,684,000 | -39.6% | 938,005 | +15.1% | 0.02% | -23.8% |
| Q3 2018 | $17,692,000 | -16.6% | 815,297 | -32.1% | 0.02% | -25.0% |
| Q2 2018 | $21,213,000 | +30.2% | 1,200,505 | +55.1% | 0.03% | +27.3% |
| Q1 2018 | $16,292,000 | -22.7% | 773,968 | -46.8% | 0.02% | -24.1% |
| Q4 2017 | $21,068,000 | -12.9% | 1,454,944 | -5.1% | 0.03% | -21.6% |
| Q3 2017 | $24,190,000 | +322.1% | 1,532,964 | +334.7% | 0.04% | +236.4% |
| Q1 2017 | $5,731,000 | -21.9% | 352,647 | -27.5% | 0.01% | -26.7% |
| Q4 2016 | $7,341,000 | -12.5% | 486,493 | -11.7% | 0.02% | +7.1% |
| Q3 2016 | $8,393,000 | -65.1% | 550,703 | -11.2% | 0.01% | -74.5% |
| Q2 2016 | $24,066,000 | -35.1% | 619,937 | -53.5% | 0.06% | -40.9% |
| Q1 2016 | $37,086,000 | -35.8% | 1,334,030 | +24.2% | 0.09% | -23.1% |
| Q4 2015 | $57,754,000 | +100.3% | 1,073,684 | +49.1% | 0.12% | +120.0% |
| Q3 2015 | $28,837,000 | +58.8% | 720,212 | +26.7% | 0.06% | +57.1% |
| Q2 2015 | $18,162,000 | +6162.8% | 568,444 | +3210.3% | 0.04% | +3400.0% |
| Q2 2014 | $290,000 | +1.0% | 17,172 | +8.8% | 0.00% | 0.0% |
| Q1 2014 | $287,000 | – | 15,781 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |